L-Homoproline is supplied as the zwitterionic free amino acid under the product model designation H-Pip-OH, with CAS Registry Number 3105-95-1 and EC number 221-462-1. The compound is (S)-piperidine-2-carboxylic acid, also classified as L-pipecolic acid, with molecular formula C₆H₁₁NO₂ and molecular weight 129.16 g/mol. Theoretical elemental analysis is C 55.79%, H 8.58%, N 10.84%, O 24.78%. The product is available in two release grades: reagent grade at ≥98.0% HPLC purity and high-purity grade at ≥99.0% HPLC purity with ≥99.5% enantiomeric excess. The physical form is a white to off-white crystalline powder. A 1% aqueous solution typically gives pH 5.0–6.0. The unprotected amino acid is freely soluble in water at 25°C, sparingly soluble in ethanol, and practically insoluble in diethyl ether. Fmoc-L-Homoproline-OH is the corresponding N-fluorenylmethoxycarbonyl protected monomer used in solid-phase peptide synthesis, with the same stereochemical specification after deprotection.

Release specifications for L-homoproline are derived from polarimetry, chiral HPLC, non-aqueous titration, loss on drying, residue on ignition, and elemental impurity analysis. The acceptance limits and method designations are listed in Table 1. Non-conformances in specific rotation or enantiomeric excess are cause for batch rejection because the material is used as a chiral building block.

Storage and process boundaries for L-homoproline are fixed by its zwitterionic structure and secondary amine reactivity. The unopened container should be stored at 2–8°C under argon or nitrogen. If ambient relative humidity exceeds 60%, the powder absorbs water; for anhydrous coupling, pre-drying is performed under vacuum at 60°C for 4 h to reduce water content below 0.2%. The material should not be mixed with nitrosating agents under acidic pH because the secondary amine can form N-nitroso derivatives, which are controlled under ICH M7 as potential mutagenic impurities. Strong oxidizers can degrade the piperidine ring; therefore, chromic acid and hypochlorite solutions are incompatible. The product is stable for 24 months when stored as recommended. If the container is opened repeatedly at high humidity, the lot-specific loss on drying should be rechecked before use.

Stereochemical Integrity and Chiral HPLC Release Criteria

Chiral purity is a critical release variable because the two enantiomers of pipecolic acid have opposite biological activity in most systems. The high-purity grade is released with an enantiomeric excess of ≥99.5%, determined by chiral HPLC on a Crownpak CR(+) column using 0.1 M HClO₄ mobile phase at 0.4 mL/min and 25°C, with UV detection at 200 nm. Under these conditions, the L-enantiomer elutes before the D-enantiomer, and the resolution factor is typically not less than 1.5. Specific rotation is measured in water at 20°C using a 1 dm polarimeter cell. Values for high-purity L-homoproline fall between -25.0° and -28.0°. Drift toward less negative rotation indicates the presence of D-homoproline or degradation products; both are quantitated in the related-substances method. In production-scale recrystallization, enantiomeric enrichment is achieved from aqueous ethanol at 0–5°C. Cooling below -5°C can co-precipitate inorganic salts, and repeated cycles above 20°C do not improve chemical purity once the product has reached the wall-solubility boundary.

How Does the Six-Membered Ring Affect Amide Isomerism and Backbone Preorganization?

Published model amide studies demonstrate that L-homoproline does not behave as a simple homolog of L-proline. In aqueous buffer at pH 7.0 and 25°C, the cis-amide population of Ac-Pip-NHMe is approximately 30–36%, while Ac-Pro-NHMe under the same conditions is approximately 12–15%. The exact ratio shifts with solvent polarity, temperature, and the acyl capping group, but the trend is consistent: the six-membered piperidine ring increases the accessible cis-amide geometry compared with the five-membered pyrrolidine ring. This affects peptide reverse-phase HPLC peak shape because cis/trans interconversion is slow on the chromatographic time scale. Columns operated at 55–60°C or mobile phases containing 0.1% formic acid are often required to collapse split peaks. In peptide design, L-homoproline therefore acts as a conformational probe that retains cyclic constraint but shifts backbone ψ angle distributions and cis-amide ratios relative to proline. This distinction is used in medicinal chemistry to test whether a target binding site requires the higher cis-amide population or the altered ring pucker.

Because of this conformational shift, L-homoproline is not freely interchangeable with L-proline in process chemistry. In solid-phase peptide synthesis, Fmoc-L-homoproline is coupled with pre-activation by HATU and DIPEA in DMF at 0–4°C. Carbodiimide-mediated activation at room temperature can increase D-pipecolate formation above 2% in hindered sequences. On automated microwave synthesizers, a 0.1 mmol scale coupling uses 2.0 equivalents of Fmoc-L-homoproline, 2.0 equivalents of HATU, and 4.0 equivalents of DIPEA in DMF at 50°C for 5 min. The lower coupling rate relative to proline is compensated by double coupling; the second coupling is performed at 50°C for 5 min after draining the first activated solution. After cleavage with TFA/triisopropylsilane/water (95:2.5:2.5 v/v/v), enantiomeric purity of the peptide is confirmed by chiral HPLC. For solution-phase peptide synthesis, mixed anhydride formation with isobutyl chloroformate and N-methylmorpholine in THF at -15°C to -5°C is preferred for pilot-scale batches because the exotherm is controlled below 0°C. The crude product is isolated by pH adjustment to 6.0–6.5, at which point the zwitterion crystallizes from aqueous media.

When L-Homoproline Replaces L-Proline in Solid-Phase Peptide Synthesis

Replacement of L-proline with L-homoproline in a peptide sequence changes the steric and electronic environment at the amide bond but preserves the secondary amine geometry needed for turn formation. The piperidine ring is more flexible than pyrrolidine, and the N-acyl derivative has a higher cis-amide population. In process development, this replacement requires revalidation of coupling yield, racemization, and cleavage because the homoproline residue is more hindered at the α-carbon. Published production-scale data for this specific substitution are limited; however, laboratory and pilot studies indicate that coupling yields may be reduced by 5–15% relative to proline under identical HBTU/HOBt conditions in DMF at 25°C. This is assigned to increased steric shielding of the piperidine nitrogen. Process transfers therefore require conservative mixing and longer coupling times when the resin substitution exceeds 0.4 mmol/g.

Pharmaceutical intermediate use is concentrated in the pipecoloxylidide class of local anesthetics. L-Homoproline is the chiral pool starting material for the (S)-piperidine-2-carboxamide scaffold found in ropivacaine. The synthesis is performed by N-alkylation of the secondary amine with 1-bromopropane in aqueous sodium carbonate at 50–60°C, followed by amide formation with 2,6-dimethylaniline using thionyl chloride or a carbodiimide. Enantiomeric purity of the final base is controlled by chiral HPLC; the R-enantiomer is limited to 0.5% in the drug substance under ICH Q3A. The same scaffold is used in other chiral amide intermediates, but the exact process fit depends on the N-alkyl group because longer alkyl chains reduce water solubility of the intermediate and require solvent switch from water to toluene or ethyl acetate. This solvent switch is a critical operational boundary in pilot-plant reactors; inadequate removal of water before amidation leads to hydrolysis of the activating agent and low conversion.

Comparative release and chemical profiles against L-proline, trans-4-hydroxy-L-proline, and D-homoproline are shown in Table 2. L-Proline has a five-membered pyrrolidine ring and a lower cis-amide population in model amides. trans-4-Hydroxy-L-proline introduces a hydroxyl substituent that stabilizes collagen-like triple-helical structures and requires additional controls for esterification by-products during coupling. D-Homoproline is the enantiomer of L-homoproline and serves the opposite stereochemical demand; its specific rotation is positive under the same conditions. DL-pipecolic acid, when supplied as a racemate, requires resolution or asymmetric synthesis because the enantiomeric ratio is not suitable for chiral drug substance synthesis without additional processing.

In practical purchasing decisions, L-homoproline is specified by the three release attributes that most affect downstream chemistry: enantiomeric excess, residual water, and heavy metal content. The high-purity grade is required for GMP pharmaceutical intermediate synthesis, while the reagent grade is used in medicinal chemistry and peptide research. The product is not approved as an excipient or active pharmaceutical ingredient by itself; it is an intermediate that requires further chemical transformation. For any lot, the certificate of analysis should be reviewed against the acceptance limits of the intended process, because differences in residual chloride, sodium, or solvent content can shift pH and catalyst performance in sensitive coupling reactions.